Inclusion of young adolescents in policy development for new tuberculosis vaccines.
The Lancet. Global health·
- DOI
- 10.1016/s2214-109x(26)00017-3
- PMID
- 42259345
- PMCID
- —
- OpenAlex
- W7163919376
- Study type
- Journal article
- Publisher
- Publisher unavailable
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Policymakers must integrate these operational hurdles into immunization planning to prevent systematic exclusion of younger demographics from emerging therapeutic protections.
Structured evidence summary
Research question
Should current immunization frameworks formally incorporate children aged nine to fourteen into tuberculosis vaccine planning, and what methodological modifications are necessary?
Study design
The manuscript operates as a policy commentary and methodological proposal, synthesizing epidemiological observations with proposed clinical trial architectures rather than presenting primary empirical data.
Population and setting
The analysis focuses on preteen and early adolescent cohorts between nine and fourteen years old, while referencing adult populations primarily for comparative licensure benchmarks.
Main findings
Early immunization provides preventive advantages before age-dependent susceptibility rises and aligns with routine school-based health initiatives. Conducting trials in this demographic presents obstacles such as sparse disease occurrence, limited prior infection markers, and diluted projected community-wide effects. The authors recommend utilizing recent household contact tracing to accelerate case identification and validate immunological markers.
Public-health relevance
Policymakers must integrate these operational hurdles into immunization planning to prevent systematic exclusion of younger demographics from emerging therapeutic protections.
Important limitations
Trial execution faces inherent constraints due to infrequent disease manifestation within the target age bracket and insufficient prior pathogen exposure to facilitate immune marker translation from adult studies. Additionally, population-level benefit projections appear comparatively subdued relative to broader adult outreach efforts, with potential multi-year delays in detecting impact if interventions target only previously infected individuals.
GIDS interpretation
This publication situates adolescent immunization strategy within broader health system planning, emphasizing how trial architecture directly influences policy adoption speed and demographic coverage metrics.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 10 auditable classifier relationships to diseases, places, topics, and study design.